In reaction to disappointing earnings/guidance:
- GNFT -10.3%
Other news:
- ANAB -8.6% (reports topline data from interim analysis of GALLOP Phase 2 clinical trial of ANB019 monotherapy in moderate-to-severe generalized pustular psoriasis)
- ELAN -1.5% (announces restructuring, to elmiminate 250 positions)
- CS -1% (Credit Suisse issues statement on the findings of the investigation into the observation of Iqbal Khan; COO Bouée Pierre-Olivier Bouée to resign)
- AZN -0.8% (announces that the FDA has issued a complete response letter regarding the New Drug Application for PT010; co will now work closely with the FDA regarding next steps)
Analyst comments:
- XLNX -1.3% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)
- FPRX -1.2% (downgraded to Neutral from Buy at Guggenheim)
- CE -1.1% (downgraded to Neutral from Buy at Goldman)
- SLG -0.6% (downgraded to Hold from Buy at Stifel)
- SLCA -0.5% (downgraded to Market Perform from Outperform at Cowen)